(Reuters) - Johnson & Johnson reported a higher-than-expected quarterly profit, driven by its pharmaceutical business and its recent acquisition of Swiss biotech Actelion and other businesses.

Pharma business, Actelion buy drive J&J's profit beat
Read More
Bagikan Berita Ini
0 Response to "Pharma business, Actelion buy drive J&J's profit beat"
Posting Komentar